MRNA therapeutic compositions
US20240148853
2024-05-09
Human necessities
A61K39/12
Inventors:
Assignee:
Applicant:
Drawings (4 of 41)
Smart overview of the Invention
The disclosed technology focuses on multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. These therapies aim to treat HPV-driven cancers and related diseases by addressing the underlying HPV infection. The application includes details on formulations, administration methods, and accompanying kits.
Background on HPV-Related Cancers
HPV is a leading cause of various cancers, including cervical and oropharyngeal cancers. Despite effective prophylactic vaccines, many women remain at risk of developing cervical intraepithelial neoplasia (CIN) due to ineligibility or personal choice against vaccination. Current treatments often fail to eradicate HPV infections, leading to high recurrence rates and associated risks, such as preterm birth. Therefore, there is a significant need for non-surgical therapeutic alternatives.
Key Aspects of the Invention
This invention introduces isolated polypeptides and polynucleotides encoding membrane-stabilized LIGHT proteins. These components are designed to enhance immune responses against HPV-related cancers. The polynucleotides feature specific sequences and modifications to improve stability and efficacy in delivering therapeutic effects.
Technical Composition Details
- The mRNA constructs include a sequence formula: 5′UTR-Signal/Leader-mRNA coding region-3′ UTR-PolyA.
- The invention incorporates nucleobase-sugar-internucleoside linkages with various modifications for enhanced performance.
- Membrane-stabilized LIGHT modifications involve linkers like antibody variable region linkers or peptide linkers, enhancing protein stability.
Potential Impact and Applications
The compositions may include additional mRNA encoding checkpoint inhibitors or pro-inflammatory agents, such as interleukin-12, to boost immune responses. This approach could significantly improve treatment outcomes for patients with persistent HPV infections and associated cancers by targeting both the disease and its root causes.